Comparative evaluation of patients newly initiating first-generation versus second-generation tyrosine kinase inhibitors for chronic myeloid leukemia and medication adherence, health services utilization, and healthcare costs

Melea A. WardUniversity of North Carolina, Department of Pharmaceutical Outcomes and Policy, Chapel Hill, NC, USACorrespondence[email protected]

Gang FangUniversity of North Carolina, Department of Pharmaceutical Outcomes and Policy, Chapel Hill, NC, USA

Kristy L. RichardsLineberger Comprehensive Cancer Center, Division of Hematology/Oncology, Chapel Hill, NC, USA

Christine M. WalkoUniversity of North Carolina, Department of Pharmacotherapy and Experimental Therapeutics, Chapel Hill, NC, USA;DeBartolo Family Personalized Medicine Institute, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA

Stephanie R. EarnshawRTI Health Solutions, RTI International, Research Triangle Park, NC, USA

Laura E. HappeHumana Inc., Louisville, KY, USA

Susan J. BlalockUniversity of North Carolina, Department of Pharmaceutical Outcomes and Policy, Chapel Hill, NC, USA

show all

Comparative evaluation of patients newly initiating first-generation versus second-generation tyrosine kinase inhibitors for chronic myeloid leukemia and medication adherence, health services utilization, and healthcare costs

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Comparative evaluation of patients newly initiating first-generation versus second-generation tyrosine kinase inhibitors for chronic myeloid leukemia and medication adherence, health services utilization, and healthcare costs

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date